Osteosarcoma: Evolution of Treatment Paradigms
Open Access
- 27 May 2013
- journal article
- review article
- Published by Hindawi Limited in Sarcoma
- Vol. 2013, 1-7
- https://doi.org/10.1155/2013/203531
Abstract
This paper reviews the contribution of chemotherapy in the conquest of osteosarcoma. It discusses how the treatment of osteosarcoma has evolved over the last five decades, resulting in a more than fivefold increase in survival. Though the initial improvements in survival were dramatic, essentially there has been no change in the outlook for this disease over the past 30 years. The paper also highlights the necessity of a multidisciplinary approach to combat this disease and stresses the need to explore newer treatment agents in order to build on the lessons learnt from the past while striving to achieve greater levels of success.Keywords
This publication has 51 references indexed in Scilit:
- A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical EraSarcoma, 2012
- Proton‐based radiotherapy for unresectable or incompletely resected osteosarcomaCancer, 2011
- Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcomaJournal of Pediatric Surgery, 2006
- Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?Cancer, 2002
- The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the ExtremityThe New England Journal of Medicine, 1986
- Osteosarcoma: Intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP): Angiographic, pathologic, and pharmacologic studiesCancer, 1983
- Cis‐diamminedichloroplatinum (NSC‐119875) in childhood malignancies: A southwest oncology group studyMedical and Pediatric Oncology, 1978
- Clinical trials with adriamycinCancer, 1971
- l-Phenylalanine mustard as a treatment for metastatic osteogenic sarcoma in childrenThe Journal of Pediatrics, 1963
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)The New England Journal of Medicine, 1948